Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

CRNX

Crinetics Pharmaceuticals Inc

Dec 13 • 04:00PM ET

53.66

Dollar change -1.96
Percentage change -3.52	%

Healthcare • Biotechnology • USA • NASD

Peers: NBIX LLY PFE NVS BMRN VRTX REGN SNY MRK BMY

| Held by: VTI IWM VXF VB XBI IWO VBK IBB SCHA VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.72	Insider Own	6.31%	Shs Outstand	92.74M	Perf Week	-8.85%
Market Cap	4.80B	Forward P/E	-	EPS next Y	-3.86	Insider Trans	-3.69%	Shs Float	86.89M	Perf Month	-8.93%
Income	-277.91M	PEG	-	EPS next Q	-0.89	Inst Own	88.23%	Short Float	6.92%	Perf Quarter	-0.52%
Sales	0.00M	P/S	-	EPS this Y	-0.31%	Inst Trans	2.14%	Short Ratio	8.31	Perf Half Y	18.38%
Book/sh	10.30	P/B	5.21	EPS next Y	-4.36%	ROA	-35.20%	Short Interest	6.01M	Perf Year	55.85%
Cash/sh	9.64	P/C	5.57	EPS next 5Y	-	ROE	-40.26%	52W Range	32.64 - 62.53	Perf YTD	50.82%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-10.59%	ROI	-31.65%	52W High	-14.19%	Beta	0.58
Dividend TTM	-	Quick Ratio	16.38	Sales past 5Y	64.83%	Gross Margin	-	52W Low	64.40%	ATR (14)	2.49
Dividend Ex-Date	-	Current Ratio	16.38	EPS Y/Y TTM	-2.14%	Oper. Margin	-	RSI (14)	40.96	Volatility	5.96% 4.52%
Employees	290	Debt/Eq	0.06	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.21	Target Price	74.00
Option/Short	Yes / Yes	LT Debt/Eq	0.05	EPS Q/Q	5.15%	Payout	-	Rel Volume	1.03	Prev Close	55.62
Sales Surprise	-100.00%	EPS Surprise	-5.41%	Sales Q/Q	-	Earnings	Nov 12 AMC	Avg Volume	723.64K	Price	53.66
SMA20	-5.14%	SMA50	-5.46%	SMA200	6.65%	Trades		Volume	748,842	Change	-3.52%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-06-24	Initiated	Citigroup	Buy	$68
Jan-16-24	Initiated	Morgan Stanley	Overweight	$50
Dec-21-23	Initiated	Jefferies	Hold	$35
Nov-20-23	Resumed	JP Morgan	Overweight	$35
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight	$52 → $50
Aug-31-23	Initiated	Oppenheimer	Outperform	$40
Apr-24-23	Initiated	Piper Sandler	Overweight	$56
Mar-30-23	Initiated	Robert W. Baird	Outperform	$48
Nov-30-21	Initiated	JMP Securities	Mkt Outperform	$43
Nov-23-21	Initiated	Evercore ISI	Outperform	$68
Jun-18-21	Upgrade	JP Morgan	Neutral → Overweight	$28
Dec-23-19	Initiated	ROTH Capital	Buy	$37
Feb-14-19	Initiated	H.C. Wainwright	Buy	$35
Aug-13-18	Initiated	Piper Jaffray	Overweight	$40
Aug-13-18	Initiated	Leerink Partners	Outperform	$43
Aug-13-18	Initiated	JP Morgan	Neutral	$29

Show Previous Ratings

Dec-10-24 08:44PM	Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.21%
06:22AM	FDA accepts Crinetics Pharmaceuticals' NDA for acromegaly treatment therapy (Pharmaceutical Business Review)
Dec-09-24 08:00AM	Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly (GlobeNewswire)
Nov-15-24 09:00AM	Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences (GlobeNewswire) -8.28%
Nov-14-24 04:05PM	UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting (GlobeNewswire)
02:18AM	Loading…
Nov-13-24 02:18AM	Crinetics Pharmaceuticals Inc (CRNX) Q3 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Nov-12-24 04:07PM	Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting (GlobeNewswire)
04:05PM	Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-11-24 04:05PM	Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-17-24 03:09PM	State Street Corp's Strategic Acquisition in Crinetics Pharmaceuticals (GuruFocus.com)
Oct-16-24 08:00AM	Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024 (GlobeNewswire)
Oct-10-24 04:40PM	Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:57AM	Morning Movers: Arcadium Lithium surges after deal to be acquired (TipRanks)
Oct-09-24 05:56PM	Crinetics Pharmaceuticals Inc (CRNX) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Oct-08-24 11:55PM	Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire)
04:01PM	Loading…
04:01PM	Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Sep-26-24 04:05PM	Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly (GlobeNewswire)
Sep-12-24 07:00PM	Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ... (GuruFocus.com) +5.02%
Sep-10-24 04:40PM	Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-05-24 01:07AM	Crinetics Pharmaceuticals, Inc. (CRNX): Among the Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Sep-02-24 06:05PM	10 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-29-24 04:05PM	Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-28-24 07:01PM	Insider Sale: Chief Scientific Officer Stephen Betz Sells 3,000 Shares of Crinetics ... (GuruFocus.com)
Aug-14-24 07:02PM	Insider Sale: Chief Scientific Officer Stephen Betz Sells 3,000 Shares of Crinetics ... (GuruFocus.com)
Aug-12-24 04:05PM	Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-08-24 09:57PM	CRNX Stock Earnings: Crinetics Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024 (InvestorPlace) +5.05% -6.11%
06:00PM	Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
08:30AM	Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges (GlobeNewswire)
Aug-01-24 10:01AM	Crinetics Pharmaceuticals, Inc. (CRNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
07:00PM	Loading…
Jul-26-24 07:00PM	Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ... (GuruFocus.com)
Jul-18-24 04:05PM	Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024 (GlobeNewswire)
Jul-12-24 07:01PM	Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ... (GuruFocus.com)
Jul-10-24 07:29PM	Crinetics Pharmaceuticals Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.33%
Jun-26-24 07:00PM	Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ... (GuruFocus.com) -5.97%
02:11PM	7 Biotech Stocks to Boost Your Portfolio to Peak Health (InvestorPlace)
Jun-18-24 04:30PM	EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year 2024 Pacific Southwest Award Winner (GlobeNewswire)
Jun-12-24 02:38AM	Insider Sale at Crinetics Pharmaceuticals Inc (CRNX): Chief Scientific Officer Stephen Betz ... (GuruFocus.com) +6.60%
Jun-10-24 06:35PM	Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-03-24 12:16PM	Crinetics Unveils 'Stunning' Results In Highly Anticipated Study (Investor's Business Daily)
12:00PM	Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly (GlobeNewswire)
12:00PM	Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing's Syndrome (ADCS) (GlobeNewswire)
May-31-24 02:46AM	Insider Sale: Chief Scientific Officer Stephen Betz Sells 3,000 Shares of Crinetics ... (GuruFocus.com)
May-30-24 04:05PM	Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs (GlobeNewswire)
May-22-24 08:00AM	Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts (GlobeNewswire)
May-16-24 05:23PM	Stanley Druckenmiller Bet On Biotech, Financial Services in Q1, Trimmed Nvidia Stake (Investopedia)
May-13-24 10:53AM	Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 05:38PM	Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
05:03PM	Crinetics Pharmaceuticals Insider Sold Shares Worth $5,307,931, According to a Recent SEC Filing (MT Newswires)
12:47PM	Crinetics Pharmaceuticals Inc (CRNX) Reports Q1 2024 Financial Results (GuruFocus.com)
May-09-24 08:55PM	CRNX Stock Earnings: Crinetics Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:35PM	Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
05:03PM	Crinetics Pharmaceuticals Q1 Net Loss Widens (MT Newswires)
04:05PM	Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-08-24 04:05PM	Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024 (GlobeNewswire) +6.78%
May-07-24 08:55AM	Piper Sandler Adjusts Price Target on Crinetics Pharmaceuticals to $97 From $56, Maintains Overweight Rating (MT Newswires)
May-02-24 04:05PM	Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024 (GlobeNewswire)
Apr-11-24 04:05PM	Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.16%
Mar-28-24 08:10AM	Insiders Are Dumping These 5 Healthcare Stocks (Insider Monkey) +5.36%
Mar-26-24 07:01PM	Insider Sell: COO Jeff Knight Sells 32,359 Shares of Crinetics Pharmaceuticals Inc (CRNX) (GuruFocus.com)
Mar-22-24 07:02PM	Insider Sell: Chief Medical and Development Officer Dana Pizzuti Sells 15,089 Shares of ... (GuruFocus.com)
07:02PM	Director Matthew Fust Sells 60,000 Shares of Crinetics Pharmaceuticals Inc (CRNX) (GuruFocus.com)
Mar-21-24 02:32AM	Crinetics Pharmaceuticals Inc CFO Marc Wilson Sells 6,942 Shares (GuruFocus.com)
Mar-20-24 11:46AM	Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals (Zacks)
05:14AM	Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar? (Zacks)
Mar-19-24 04:48PM	Endocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here's Why (Benzinga) +19.11%
04:03PM	Crinetics Stock Jets 19% Higher, Reversing A Three-Week Decline On Its Phase 3 Win (Investor's Business Daily)
08:08AM	Biotech Stock Crinetics Jets Higher On Second Phase 3 Trial Win (Investor's Business Daily)
06:16AM	UPDATE 2-Crinetics' hormonal disorder drug succeeds in late-stage study (Reuters)
06:08AM	Crinetics Pharma's hormonal disorder drug meets main goal in late-stage study (Reuters)
06:00AM	Crinetics' Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients (GlobeNewswire)
Mar-12-24 04:05PM	Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome (GlobeNewswire)
Mar-11-24 04:05PM	Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-01-24 08:57AM	Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q4 2023 Earnings Call Transcript (Insider Monkey) +12.43%
Feb-28-24 04:36PM	Crinetics Pharmaceuticals Inc (CRNX) Reports Increased R&D Investment Amidst Net Loss ... (GuruFocus.com) +5.66%
04:05PM	Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
08:00AM	Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement (GlobeNewswire)
Feb-15-24 03:14AM	Steven Cohen Adjusts Position in Crinetics Pharmaceuticals Inc (GuruFocus.com)
Feb-14-24 04:05PM	Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024 (GlobeNewswire)
Feb-12-24 04:05PM	Crinetics Pharmaceuticals Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.42%
Jan-26-24 11:01PM	Crinetics Pharmaceuticals Inc's Chief Scientific Officer Sells Company Shares (GuruFocus.com)
Jan-13-24 05:03AM	Crinetics Pharmaceuticals Inc Insider Sells Shares (GuruFocus.com)
Jan-10-24 04:33PM	Crinetics Pharmaceuticals Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-05-24 03:03AM	Insider Sell: Chief Med and Dev Officer Dana Pizzuti Sells 14,375 Shares of Crinetics ... (GuruFocus.com)
Jan-03-24 08:00AM	Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-29-23 07:02AM	Crinetics Pharmaceuticals Inc's Chief Scientific Officer Sells Shares (GuruFocus.com)
Dec-23-23 05:01AM	Insider Sell: Chief Med and Dev Officer Dana Pizzuti Sells 9,583 Shares of Crinetics ... (GuruFocus.com)
Dec-18-23 04:05PM	Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome (GlobeNewswire) +11.49%
Dec-11-23 04:05PM	Crinetics Pharmaceuticals Announces December 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-03-23 05:25AM	12 Stocks Billionaire Steve Cohen Just Bought and Sold (Insider Monkey)
Nov-20-23 04:05PM	Crinetics Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-17-23 08:39AM	Billionaire Steve Cohen Goes Big on These 2 Strong Buy Stocks Heres Why You Should Follow (TipRanks) +5.82%
Nov-10-23 05:00PM	Crinetics Pharmaceuticals Announces November 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.01%
Nov-09-23 05:45AM	Crinetics Pharmaceuticals Inc (CRNX) Reports Q3 2023 Results: Phase 3 Success and Financial Growth (GuruFocus.com) -6.19%
Nov-08-23 09:55AM	Wall Street Analysts See a 56.94% Upside in Crinetics Pharmaceuticals, Inc. (CRNX): Can the Stock Really Move This High? (Zacks)
08:50AM	Here's What Could Help Crinetics Pharmaceuticals, Inc. (CRNX) Maintain Its Recent Price Strength (Zacks)
Nov-07-23 04:05PM	Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-04-23 05:03AM	Insider Sell: CFO Marc Wilson Sells 10,000 Shares of Crinetics Pharmaceuticals Inc (CRNX) (GuruFocus.com)
Oct-23-23 09:55AM	Wall Street Analysts Think Crinetics Pharmaceuticals, Inc. (CRNX) Could Surge 55.53%: Read This Before Placing a Bet (Zacks)
08:50AM	What Makes Crinetics Pharmaceuticals, Inc. (CRNX) a Good Fit for 'Trend Investing' (Zacks)

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Struthers Richard Scott	President & CEO	Dec 02 '24	Sale	57.57	10,000	575,700	100,000	Dec 04 04:30 PM
Struthers Richard Scott	Officer	Dec 02 '24	Proposed Sale	57.27	10,000	572,700		Dec 02 04:06 PM
Knight Jeff E.	Chief Operating Officer	Nov 22 '24	Sale	56.52	501	28,317	51,653	Nov 26 04:30 PM
Pizzuti Dana	Chief Med and Dev Officer	Oct 03 '24	Option Exercise	16.89	14,375	242,794	42,882	Oct 07 07:55 AM
Pizzuti Dana	Chief Med and Dev Officer	Oct 03 '24	Sale	54.63	14,375	785,306	28,507	Oct 07 07:55 AM
DANA J PIZZUTI	Officer	Oct 03 '24	Proposed Sale	54.63	14,375	785,322		Oct 03 04:08 PM
Wilson Marc	CFO	Sep 26 '24	Option Exercise	15.29	25,000	382,250	136,092	Sep 30 05:01 PM
Wilson Marc	CFO	Sep 26 '24	Sale	51.11	25,000	1,277,750	111,092	Sep 30 05:01 PM
MARC WILSON	Officer	Sep 26 '24	Proposed Sale	51.10	25,000	1,277,625		Sep 26 04:06 PM
Betz Stephen F.	Chief Scientific Officer	Sep 10 '24	Sale	51.50	1,035	53,302	68,576	Sep 12 04:30 PM
Betz Stephen F.	Officer	Sep 10 '24	Proposed Sale	51.50	1,035	53,301		Sep 10 12:11 PM
Betz Stephen F.	Chief Scientific Officer	Aug 26 '24	Sale	53.19	3,000	159,570	69,611	Aug 28 04:31 PM
Betz Stephen F.	Officer	Aug 26 '24	Proposed Sale	53.19	3,000	159,570		Aug 26 01:16 PM
Betz Stephen F.	Chief Scientific Officer	Aug 12 '24	Sale	47.68	3,000	143,040	72,611	Aug 14 04:30 PM
Betz Stephen F.	Officer	Aug 12 '24	Proposed Sale	47.68	3,000	143,050		Aug 12 11:35 AM
Betz Stephen F.	Chief Scientific Officer	Jul 25 '24	Sale	53.43	3,000	160,290	75,611	Jul 26 04:38 PM
Wilson Marc	CFO	Jul 25 '24	Option Exercise	9.28	19,056	176,840	130,148	Jul 26 04:24 PM
Wilson Marc	CFO	Jul 25 '24	Sale	53.88	19,056	1,026,737	111,092	Jul 26 04:24 PM
Knight Jeff E.	Chief Operating Officer	Jul 15 '24	Option Exercise	22.59	26,073	589,116	78,653	Jul 17 05:35 PM
Knight Jeff E.	Chief Operating Officer	Jul 15 '24	Sale	55.00	27,000	1,485,000	51,653	Jul 17 05:35 PM
Wilson Marc	CFO	Jul 15 '24	Option Exercise	20.02	25,000	500,500	136,092	Jul 17 05:14 PM
Wilson Marc	CFO	Jul 15 '24	Sale	55.00	25,000	1,375,000	111,092	Jul 17 05:14 PM
Betz Stephen F.	Chief Scientific Officer	Jul 10 '24	Sale	48.55	3,000	145,650	78,611	Jul 12 04:30 PM
Hassard James	Chief Commercial Officer	Jul 05 '24	Option Exercise	19.73	15,000	295,950	44,259	Jul 09 06:04 PM
Hassard James	Chief Commercial Officer	Jul 05 '24	Sale	44.08	15,000	661,200	29,259	Jul 09 06:04 PM
Pizzuti Dana	Chief Med and Dev Officer	Jul 03 '24	Option Exercise	16.89	14,375	242,794	42,882	Jul 05 04:30 PM
Pizzuti Dana	Chief Med and Dev Officer	Jul 03 '24	Sale	44.87	14,375	645,006	28,507	Jul 05 04:30 PM
Wilson Marc	CFO	Jun 28 '24	Option Exercise	9.28	32,129	298,157	143,221	Jul 02 04:32 PM
Wilson Marc	CFO	Jun 28 '24	Sale	43.61	32,129	1,401,146	111,092	Jul 02 04:32 PM
Knight Jeff E.	Chief Operating Officer	Jun 26 '24	Sale	44.38	956	42,427	52,580	Jun 28 05:31 PM
Betz Stephen F.	Chief Scientific Officer	Jun 25 '24	Sale	45.37	3,000	136,110	80,643	Jun 26 04:32 PM
Pizzuti Dana	Chief Med and Dev Officer	Jun 24 '24	Option Exercise	16.89	9,500	160,455	37,286	Jun 25 05:03 PM
Pizzuti Dana	Chief Med and Dev Officer	Jun 24 '24	Sale	45.73	9,500	434,435	27,786	Jun 25 05:03 PM
Hassard James	Chief Commercial Officer	Jun 21 '24	Option Exercise	19.73	15,000	295,950	44,259	Jun 24 05:08 PM
Hassard James	Chief Commercial Officer	Jun 21 '24	Sale	44.66	15,000	669,900	29,259	Jun 24 05:08 PM
Betz Stephen F.	Chief Scientific Officer	Jun 10 '24	Sale	43.86	3,000	131,580	83,643	Jun 11 04:35 PM
Betz Stephen F.	Chief Scientific Officer	May 28 '24	Sale	47.49	3,000	142,470	86,643	May 30 04:28 PM
Betz Stephen F.	Chief Scientific Officer	May 10 '24	Sale	49.43	3,000	148,290	89,643	May 14 06:29 PM
Struthers Richard Scott	President & CEO	May 08 '24	Option Exercise	9.28	107,448	997,117	364,933	May 10 04:57 PM
Struthers Richard Scott	President & CEO	May 08 '24	Sale	49.40	107,448	5,307,931	257,485	May 10 04:57 PM
Pizzuti Dana	Chief Med and Dev Officer	Apr 15 '24	Option Exercise	16.89	14,375	242,794	42,161	Apr 17 04:36 PM
Pizzuti Dana	Chief Med and Dev Officer	Apr 15 '24	Sale	44.47	14,375	639,256	27,786	Apr 17 04:36 PM
Struthers Richard Scott	President & CEO	Apr 15 '24	Option Exercise	1.91	20,000	38,200	257,835	Apr 17 04:30 PM
Struthers Richard Scott	President & CEO	Apr 04 '24	Option Exercise	9.28	40,951	380,025	278,786	Apr 08 05:09 PM
Struthers Richard Scott	President & CEO	Apr 04 '24	Sale	49.17	40,951	2,013,561	237,835	Apr 08 05:09 PM
Okey Stephanie	Director	Mar 28 '24	Option Exercise	18.29	17,500	320,075	23,500	Apr 02 04:35 PM
Okey Stephanie	Director	Mar 28 '24	Sale	46.38	17,500	811,650	6,000	Apr 02 04:35 PM
Knight Jeff E.	Chief Operating Officer	Mar 22 '24	Option Exercise	23.98	30,000	719,400	84,939	Mar 26 04:30 PM
Knight Jeff E.	Chief Operating Officer	Mar 22 '24	Sale	44.31	32,359	1,433,675	52,580	Mar 26 04:30 PM
Pizzuti Dana	Chief Med and Dev Officer	Mar 20 '24	Option Exercise	16.89	14,375	242,794	38,500	Mar 22 04:52 PM
Pizzuti Dana	Chief Med and Dev Officer	Mar 20 '24	Sale	44.06	15,089	664,763	27,786	Mar 22 04:52 PM
Fust Matthew K	Director	Mar 20 '24	Option Exercise	20.92	60,000	1,254,975	36,036	Mar 22 04:31 PM
Fust Matthew K	Director	Mar 20 '24	Sale	44.14	60,000	2,648,150	18,536	Mar 22 04:31 PM
Wilson Marc	CFO	Mar 19 '24	Sale	42.91	6,942	297,881	110,630	Mar 20 06:32 PM
Betz Stephen F.	Chief Scientific Officer	Jan 25 '24	Sale	37.26	3,000	111,780	73,298	Jan 26 05:50 PM
Betz Stephen F.	Chief Scientific Officer	Jan 10 '24	Sale	37.65	3,000	112,950	76,298	Jan 12 04:12 PM
Pizzuti Dana	Chief Med and Dev Officer	Jan 03 '24	Option Exercise	16.89	14,375	242,794	20,286	Jan 04 04:45 PM
Pizzuti Dana	Chief Med and Dev Officer	Jan 03 '24	Sale	35.00	14,375	503,125	5,911	Jan 04 04:45 PM
Wilson Marc	CFO	Jan 02 '24	Option Exercise	9.28	10,000	92,800	106,055	Jan 04 04:43 PM
Wilson Marc	CFO	Jan 02 '24	Sale	35.47	10,000	354,700	96,055	Jan 04 04:43 PM
Betz Stephen F.	Chief Scientific Officer	Dec 26 '23	Sale	35.89	3,000	107,670	79,298	Dec 27 05:20 PM
Pizzuti Dana	Chief Med and Dev Officer	Dec 21 '23	Option Exercise	16.89	9,583	161,857	15,494	Dec 22 06:45 PM
Pizzuti Dana	Chief Med and Dev Officer	Dec 21 '23	Sale	34.57	9,583	331,284	5,911	Dec 22 06:45 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CRNX

Crinetics Pharmaceuticals Inc

Upgrade your FINVIZ experience